Literature DB >> 21612970

Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France.

Claudine Fayard1, Audrey Bonaventure, Isabelle Benatru, Emmanuel Roze, Julien Dumurgier, Frédéric Moisan, Aïcha Soumaré, Jean Houssinot, Jean-Luc Dupupet, Jean-Louis Mazurie, Irina Balaboi, Jean-Luc Houeto, Elsa Krim, Danièle Ranoux, Marcel Goldberg, Ellen Imbernon, Thibault Moreau, Maurice Giroud, Christophe Tzourio, Alexis Elbaz.   

Abstract

Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <60 years (n = 49) and levodopa in patients ≥70 years (n = 133). Agreement with the recommendations increased after 2000 (66.0%) compared to before (46.3%, p = 0.025). For patients <60 years, agreement increased (64.0% vs 20.2%, p = 0.017) while it remained stable (66.4% vs 70.6%, p = 0.73) in patients ≥70 years. The publication of recommendations has influenced initial treatment choices for PD in France.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612970     DOI: 10.1016/j.parkreldis.2011.04.020

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.

Authors:  Pei-Chen Lee; Ismaïl Ahmed; Marie-Anne Loriot; Claire Mulot; Kimberly C Paul; Jeff M Bronstein; Beate Ritz; Alexis Elbaz
Journal:  Neurology       Date:  2018-01-19       Impact factor: 9.910

2.  Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease.

Authors:  Ismaïl Ahmed; Pei-Chen Lee; Christina M Lill; Susan Searles Nielsen; Fanny Artaud; Lisa G Gallagher; Marie-Anne Loriot; Claire Mulot; Magali Nacfer; Tian Liu; Joanna M Biernacka; Sebastian Armasu; Kari Anderson; Federico M Farin; Christina Funch Lassen; Johnni Hansen; Jørgen H Olsen; Lars Bertram; Demetrius M Maraganore; Harvey Checkoway; Beate Ritz; Alexis Elbaz
Journal:  PLoS Genet       Date:  2014-11-20       Impact factor: 5.917

Review 3.  Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.

Authors:  Khalid Orayj; Emma Lane
Journal:  Parkinsons Dis       Date:  2019-11-03

4.  Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample.

Authors:  Nabila Dahodwala; Allison W Willis; Pengxiang Li; Jalpa A Doshi
Journal:  Mov Disord Clin Pract       Date:  2016-08-22

5.  The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study.

Authors:  Clelia Pellicano; Dario Benincasa; Alessandra Fanciulli; Pamela Latino; Morena Giovannelli; Francesco E Pontieri
Journal:  Eur J Med Res       Date:  2013-12-21       Impact factor: 2.175

6.  Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis.

Authors:  Frédéric Moisan; Sofiane Kab; Fatima Mohamed; Marianne Canonico; Morgane Le Guern; Cécile Quintin; Laure Carcaillon; Javier Nicolau; Nicolas Duport; Archana Singh-Manoux; Marjorie Boussac-Zarebska; Alexis Elbaz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-12-23       Impact factor: 10.154

7.  The characteristics and treatment patterns of patients with Parkinson's disease in the United States and United Kingdom: A retrospective cohort study.

Authors:  Linda Kalilani; David Friesen; Nada Boudiaf; Mahnaz Asgharnejad
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.